Nutritional Management of Polycystic Ovarian Disease: Integrating Unani and Contemporary Approaches

Year : 2025 | Volume : 12 | 02 | Page : –
    By

    Sadaf Naaz,

  • Mahfooz ur Rehman,

  • Hina Khan,

  • Saliha,

  1. PG Scholar, H.S.Z.H Unani Medical College, Bhopal, Madhya Pradesh,
  2. H.O.D, H.S.Z.H Unani Medical College, Bhopal, Madhya Pradesh, India
  3. PG Scholar, H.S.Z.H Unani Medical College, Bhopal, Madhya Pradesh, India
  4. PG Scholar, H.S.Z.H Unani Medical College, Bhopal, Madhya Pradesh, India

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_187091’);});Edit Abstract & Keyword

In Unani medicine, dietary management, known as Ilaj bil Ghiza, plays a vital role in restoring humoral balance and maintaining a healthy temperament (mizaj). This principle aligns with modern medical understanding, particularly in conditions like Polycystic Ovarian Syndrome (PCOS), which is often associated with insulin resistance and obesity. Modifying dietary habits has shown promise in improving both metabolic and reproductive functions in PCOS patients. Unani scholars attribute PCOS to a Sue Mizaj Barid Ratab (cold and moist temperament), advising consumption of foods with hot and dry qualities. Modern perspectives support the intake of low-glycemic foods while avoiding high-glycemic ones. This review explores the dietary recommendations for managing PCOS through the lens of both Unani and contemporary medical systems.

Keywords: Sue Mizaj , Polycystic Ovarian Disease, Unani, Epidemiology, Pathophysiology

How to cite this article:
Sadaf Naaz, Mahfooz ur Rehman, Hina Khan, Saliha. Nutritional Management of Polycystic Ovarian Disease: Integrating Unani and Contemporary Approaches. Research & Reviews : A Journal of Unani, Siddha and Homeopathy. 2025; 12(02):-.
How to cite this URL:
Sadaf Naaz, Mahfooz ur Rehman, Hina Khan, Saliha. Nutritional Management of Polycystic Ovarian Disease: Integrating Unani and Contemporary Approaches. Research & Reviews : A Journal of Unani, Siddha and Homeopathy. 2025; 12(02):-. Available from: https://journals.stmjournals.com/rrjoush/article=2025/view=0



document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_187091’);});Edit

References

  1. Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2019;2019:CD007506.
  2. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. J Pediatr Adolesc Gynecol 2011;24:223‑7.
  3. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853‑61.
  4. Ratnakumari ME, Manavalan N, Sathyanath D, Ayda YR, Reka K. Study to evaluate the changes in polycystic ovarian morphology after naturopathic and yogic interventions. Int J Yoga 2018;11:139‑47.
  5. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and Pcos society disease state clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome‑Part 2. Endocr Pract 2015;21:1415‑26.
  6. Salari, N., Nankali, A., Ghanbari, A. et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis. Arch Gynecol Obstet (2024). https://doi.org/10.1007/s00404-024-07607-x
  7. Ganie, Mohammad Ashraf; Vasudevan, Vishnu; Wani, Imtiyaz Ahmad; Baba, Mohammad Salem; Arif, Tasleem; Rashid, Aafia. Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. Indian Journal of Medical Research 150(4):p 333-344, October 2019. | DOI: 10.4103/ijmr.IJMR_1937_17
  8. Barberi RL. Induction of ovulation in infertile women hyperandrogenism and insulin resistance. Am J Obstet Gynecol.2000;183:1412-1418.
  9. Mac Pannill. Polycystic Ovary Syndrome:An Overview. Topics in Advanced Practice Nursing eJournal. 2002;2(3)
  10. Poretsky L, Piper B. Insulin resistance,hypersensitivity of LH, and dual defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol. 1994;84:613-621
  11. Barberi RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosisnigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol. 1983; 147:90 101.
  12. Barberi RL. Some genetic syndromes associated with hyperandrogenism. ContempObstet Gynecol. 1994; 39:35-48.
  13. Kidson W. Polycystic ovary syndrome: a new direction I treatment. Med J Aust.1998; 169:537-540. Available athttp://www.mja.com.au/public/issues/nov16/kidson/kidson.html.
  14. Lobo RA, Camina E. The importance of diagnosing the polycystic ovary syndrome.Ann Intern Med. 2000;132:989-993.http://www.geocities.ws/mim_subspec/AnnIntMed-PCOS.pdfon Monday, May 16,2016.
  15. Razi ABZ. Al Hawi-Fil-Tib, Vol. IX. New Delhi: CCRUM; 2001: 151-68.
  16. Bhat SA et al., Clinical Study of Polycystic Ovarian Syndrome with a Unani Formulation: A Randomized Single-Blind Placebo Controlled Study. American Journal of Pharmacy & Health Research 2015.
  17. Ibn-e-Hubal Baghdadi. Kitab-al-MukhtaratFil Tibb, Vol II &Vol IV NewDelhi: CCRUM; 2007: Vol II 50-51, 57-58,74-75, 77-78, 100-101,112-113, 213-215.Vol IV 31-35
  18. Majoosi ABA. Kamil-us-Sanaa (Urdu translation by Kantoori GH) MunshiNawalKishore, Lucknow.1889: 110-112,486-488
  19. Mohammed Tabri, Moalijat e Buqratiya (Urdu), Part 3rd CCRUM,New Delhi PageNo. 215- 216
  20. IbnSina. Al QanoonFilTib (Urdu translation by Kantoori GH). New Delhi:IdaraKitab-us-shifa; 2010: 280, 328, 1088-89, 1095- 98.
  21. Jurjani I. ZakheeraeKhawarzamShahi(Urdu trans. by Khan AH). Vol VI. NewDelhi: IdaraKitab-us-shifa; 2010 January:597-602
  22. Qumri AMH. GhinaMuna. 1sted. New Delhi:CCRUM; 2008:410-413, 435-437.
  23. Khan A. Al Akseer (Urdu translation by Kabeeruddin). New Delhi: IdaraKitab-usshifa;2011January: 797-801.
  24. Deshpande S et al. Effect of Polyherbal Formulation in Treatment of Poly Cystic Ovarian Syndrome (PCOS), IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-ISSN: 2278 3008.Volume5, Issue 5 (Mar. – Apr. 2013), PP 63-66
  25. Wang HS, Wang TH. Polycystic ovary syndrome (PCOS), insulin resistance and insulin-like growth factors (IGfs)/IGFbinding proteins (IGFBPs). Chang Gung Med J 2003;26:540-53.
  26. Ortega-Gonzalez C, Luna S, Hernandez L,Crespo G, Aguayo P, Arteaga-Troncoso G,
  27. Parra A. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J ClinEndocrinolMetab 2005; 90:1360-5.
  28. U.S. Department of Health and Human Services, Office of Women’s Health.(2010).Polycystic ovary syndrome (PCOS) fact sheet. Retrieved April 24, 2012, fromhttp://www.womenshealth.gov/publications/our-publications/factsheet/polycystic-ovary syndrome.html
  29. Ferriman-Gallowey scoring system for hirsutism. Reproduced with permission of publisher from Barbieri RL: V Polycystic Ovary Syndrome. 16 Women’s Health.WebMD Scientific American® Medicine Online. Dale DC, Federman DD, Eds.WebMD Corporation, New York,2002. http://www.samed.com)
  30. Slowey MJ. Polycystic ovary syndrome:new perspective on an old problem. South Med J. 2001;94:190-196.
  31. Dokras A, Clifton S, Futterweit W, Wild R.Quality of Life Issues and PCOS. FertilSteril 2012;97:225-30.
  32. Hameed L, Farooq AD, Qureshi T, Mohiuddin E. Dietary management of Takayus al mebyadh (polycystic ovarian syndrome). Hamdard Medicus. 2017;6(1):67-81.
Ahead of Print Subscription Review Article
Volume 12
02
Received 26/04/2025
Accepted 29/04/2025
Published 30/04/2025
Publication Time 4 Days
128

[first_name] [last_name]

My IP

PlumX Metrics